The Society for Immunotherapy of Cancer (SITC) will host the Summit on Intrallesional Immunotherapy: Moving Beyond Oncolytic Viruses on Thursday, Sept. 19, from 10 a.m.–2 p.m. EDT. The virtual summit is a free, public event that features invited speakers, expert panel discussions, and attendee question and answer periods. The multi-stakeholder virtual summit will feature over 25 panelists representing academic research and industry around the world.

PROGRAM SUMMARY
The SITC Summit on Intrallesional Immunotherapy will highlight the latest translational and clinical research on intrallesional immunotherapies and their impacts on the immune system, anti-tumor immunity, and the tumor microenvironment. Topics to be addressed at the summit include the current definitions of local immunotherapy, enhancing the effects of in situ vaccination, combining intrallesional immunotherapies with other therapies, intrallesional immunotherapy in the neoadjuvant setting, and high priority research areas for the field of intrallesional immunotherapy.

This program will provide an up-to-date overview of current and emerging intrallesional immunotherapies and their potential clinical impact. Didactic presentations and panel discussions will identify clinical and translational strategies, challenges, and opportunities in the field, highlighting intrallesional immunotherapy as an important tool in the cancer immunotherapy toolbox.

PROGRAM ORGANIZERS
Tanja de Gruijl, PhD
Amsterdam University Medical Centers

Howard Kaufman, MD, FACS
Ankyra Therapeutics/ Massachusetts General Hospital

SUMMIT GOALS & OBJECTIVES
- Highlight opportunities and challenges in the field of intrallesional immunotherapies
- Define intrallesional immunotherapy
- Explore the effects of intrallesional immunotherapies on the immune system, tumor microenvironment and anti-tumor immunity
- Articulate high-priority research areas and a path forward for the field

Register: sitc.execinc.com/edibo/VS24ILO